Skip to main content
OpenTrials
Not yet recruiting

NCT Number: NCT07773831

Efficacy and Safety of Temporal Interference Stimulation in Treatment-Resistant Schizophrenia: An Exploratory Study.

This exploratory study aims to evaluate the preliminary efficacy and safety of temporal interference (TI) stimulation in patients with treatment-resistant schizophrenia (TRS). TI is a noninvasive brain stimulation technique that uses two high-frequency electrical currents with slightly different frequencies to generate a lower-frequency modulation at a targeted deep brain region.

A total of 20 patients with TRS will receive 130-Hz TI stimulation targeting the anterior limb of the internal capsule (ALIC). Stimulation will be delivered at a total current intensity of 4 mA for 5 consecutive days, with four 40-minute sessions per day. Participants will continue their stable antipsychotic medication regimen during the study.

Clinical symptoms, cognitive function, social functioning, and safety will be assessed before treatment, after completion of the 5-day treatment course, and at a 2-week follow-up. The primary clinical outcome is the change in the Positive and Negative Syndrome Scale (PANSS) total score. Secondary assessments include PANSS subscale scores, the MATRICS Consensus Cognitive Battery (MCCB), Calgary Depression Scale for Schizophrenia (CDSS), Personal and Social Performance Scale (PSP), and Clinical Global Impression (CGI). Safety will be evaluated through daily monitoring of treatment-related discomfort and adverse events.

Magnetic resonance imaging (MRI) will also be performed before and after treatment to explore treatment-related changes in brain structure, functional activity, functional connectivity, activation, and cerebral blood flow. The study hypothesizes that TI stimulation targeting the ALIC may improve clinical symptoms in patients with TRS and may be associated with measurable changes in neuroimaging markers.

Not yet recruiting

Trial opening soon.

Get Notified

Key information

Conditions

Treatment-resistant Schizophrenia Mental Disorders Schizophrenia Schizophrenia Spectrum and Other Psychotic Disorders Schizophrenia, Treatment-Resistant

Age range

18 year–65 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Right-handed male or female participants aged 18 to 65 years, inclusive.
  • Diagnosis of schizophrenia according to the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5), established by a psychiatrist at the attending-physician level or above and confirmed by the Mini International Neuropsychiatric Interview, version 7.0.2 (MINI 7.0.2).
  • Inadequate response to sequential treatment with at least two antipsychotic medications of different chemical classes, each administered at an adequate dose (≥600 mg/day chlorpromazine equivalents) for an adequate duration (≥6 consecutive weeks at a therapeutic dose).
  • Stable dose of antipsychotic medication for at least 4 weeks before enrollment.
  • A score of 4 (moderate) or higher on at least two of the following Positive and Negative Syndrome Scale (PANSS) items: delusions, hallucinatory behavior, suspiciousness/persecution, or unusual thought content.
  • Ability to understand the study procedures, willingness to participate voluntarily and comply with the study procedures, and provision of written informed consent.

Exclusion criteria

  • Current diagnosis of another major psychiatric disorder other than schizophrenia that, in the investigator's judgment, may confound the diagnosis of schizophrenia or interfere with the assessment of treatment efficacy or safety.
  • Receipt of other neuromodulation treatments, including modified electroconvulsive therapy (MECT), repetitive transcranial magnetic stimulation (rTMS), or transcranial direct current stimulation (tDCS), within the previous 3 months, or previous participation in an interventional clinical trial involving vagus nerve stimulation (VNS) or deep brain stimulation (DBS).
  • A score ≥3 on Item 3 (suicide) of the 17-item Hamilton Depression Rating Scale (HAMD-17), or a score >3 on any of the following PANSS items: P4 Excitement, G14 Poor Impulse Control, P7 Hostility, or G8 Uncooperativeness.
  • Contraindications to magnetic resonance imaging (MRI), including intracranial metallic implants, implanted cardiac pacemakers, or cochlear implants.
  • Skull defects or fissures, or inability to tolerate stimulation-related adverse effects.
  • Treatment-resistant epilepsy or other serious medical conditions that, in the investigator's judgment, may potentially affect treatment or participation in the study.
  • Pregnancy.
  • Any other condition that, in the investigator's judgment, makes the participant unsuitable for participation in the study.

Treatment and study plan

temporal interference stimulation

Device

Participants with treatment-resistant schizophrenia will receive 130-Hz temporal interference stimulation targeting the anterior limb of the internal capsule (ALIC). Stimulation will be delivered at a total current intensity of 4 mA for 5 consecutive days, with four 40-minute sessions per day and a 20-minute interval between sessions.

Primary outcomes

  1. Change From Baseline in Positive and Negative Syndrome Scale (PANSS) Total Score at the End of Treatment

    Time frame: Baseline to Day 5

  2. Change From Baseline in Positive and Negative Syndrome Scale (PANSS) Total Score at 2-Week Follow-up

    Time frame: Baseline to Day 14 ± 2 days after treatment completion

Secondary outcomes

  1. Change From Baseline in PANSS Positive Symptom Subscale Score

    Time frame: Baseline to Day 5 and Day 14 ± 2 days after treatment completion

  2. Change From Baseline in PANSS Negative Symptom Subscale Score

    Time frame: Baseline to Day 5 and Day 14 ± 2 days after treatment completion

  3. Change From Baseline in PANSS General Psychopathology Subscale Score

    Time frame: Baseline to Day 5 and Day 14 ± 2 days after treatment completion

  4. Change From Baseline in MATRICS Consensus Cognitive Battery (MCCB) Score

    Time frame: Baseline to Day 5 and Day 14 ± 2 days after treatment completion

  5. Change From Baseline in Calgary Depression Scale for Schizophrenia (CDSS) Score

    Time frame: Baseline to Day 5 and Day 14 ± 2 days after treatment completion

  6. Change From Baseline in Personal and Social Performance Scale (PSP) Score

    Time frame: Baseline to Day 5 and Day 14 ± 2 days after treatment completion

  7. Change From Baseline in Clinical Global Impression (CGI) Score

    Time frame: Baseline to Day 5 and Day 14 ± 2 days after treatment completion

Sponsors and collaborators

Lead sponsor

Zhimin Wang

Other

Registry information

Important dates

Study start
2026
Primary completion
2027
Study completion
2027
First posted
Aug 19, 2026
Registry last updated
Aug 19, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.